Table 3.

Patient incidence of adverse events in the AMG 232 dose expansion

	WDLPS (n = 10)	DDLPS (n = 10)	GBM (n = 10)	Other Solid (n = 16)	ER + PR+ Breast (n = 8)	ER + PR–Breast (n = 4)	Multiple Myeloma (n = 10)	Total (n = 68)
Patients with any treatment-emergent AE, n (%)	10 (100)	9 (90)	10 (100)	16 (100)	8 (100)	4 (100)	10 (100)	67 (99)
Patients with any treatment-emergent serious AE, n (%)	5 (50)	4 (40)	7 (70)	5 (31)	3 (38)	1 (25)	4 (40)	29 (43)
Patients with any treatment-related AE, n (%)	10 (100)	9 (90)	10 (100)	14 (88)	8 (100)	4 (100)	10 (100)	65 (96)
Grade 3	6 (60)	0	4 (40)	4 (25)	4 (50)	1 (25)	6 (60)	25 (37)
Grade 4	3 (30)	0	0	2 (13)	0	0	3 (30)	8 (12)
Grade 5	0	0	0	0	0	0	0	0
Treatment-related AEs occurring in ≥10% of patients, n (%)
Diarrhea	9 (90)	6 (60)	5 (50)	8 (50)	7 (88)	4 (100)	7 (70)	46 (68)
Nausea	10 (100)	8 (80)	4 (40)	11 (69)	6 (75)	3 (75)	4 (40)	46 (68)
Vomiting	7 (70)	2 (20)	3 (30)	8 (50)	6 (75)	2 (50)	4 (40)	32 (47)
Fatigue	8 (80)	7 (70)	6 (60)	6 (38)	3 (38)	0	2 (20)	32 (47)
Decrease appetite	7 (70)	4 (40)	1 (10)	4 (25)	5 (63)	3 (75)	4 (40)	28 (41)
Thrombocytopenia	6 (60)	1 (10)	2 (20)	2 (13)	0	0	3 (30)	14 (21)
Neutropenia	1 (60)	0	2 (20)	1 (6)	0	0	3 (30)	12 (18)
Anemia	5 (50)	0	0	3 (19)	0	1 (25)	1 (10)	10 (15)
Asthenia	0	1 (10)	0	2 (13)	1 (13)	1 (25)	4 (40)	9 (13)
Dysgeusia	1 (10)	1 (10)	1 (10)	2 (13)	2 (25)	0	2 (20)	9 (13)
Patients with any serious, treatment-related AE, n (%)	2 (20)	0	1 (10)	0	2 (25)	0	2 (20)	7 (10)
Vomiting (grade 3)	0	0	0	0	1 (13)	0	2 (20)	3 (4)
Diarrhea (grade 3)	0	0	0	0	1 (13)	0	0	1 (2)
Nausea (grade 3)	0	0	0	0	1 (13)	0	0	1 (2)
Hyperamylasemia (grade 3)	0	0	1 (10)	0	0	0	0	1 (2)
Hyperlipasemia (grade 3)	0	0	1 (10)	0	0	0	0	1 (2)
Dehydration (grade 3)	1 (10)	0	0	0	0	0	0	1 (2)
Pulmonary embolism (grade 3)	1 (10)	0	0	0	0	0	0	1 (2)

AE, adverse event; DD, Dedifferentiated liposarcoma; WD, well differentiated liposarcoma